Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma

被引:21
作者
Dupuis, Jehan [1 ]
Gaulard, Philippe [2 ,3 ]
Hemery, Francois [4 ]
Itti, Emmanuel [5 ]
Gisselbrecht, Christian [7 ]
Rahmouni, Alain [6 ]
Copie-Bergman, Christiane [2 ,3 ]
Briere, Josette [8 ]
El Gnaoui, Taoufik [1 ]
Gaillard, Isabelle [1 ]
Meignan, Michel [5 ]
Haioun, Corinne [1 ]
机构
[1] Paris XII Univ, H Mondor Hosp, AP HP, Dept Clin Hematol, Creteil, France
[2] Paris XII Univ, H Mondor Hosp, AP HP, Dept Pathol, Creteil, France
[3] Paris XII Univ, H Mondor Hosp, AP HP, INSERM U617, Creteil, France
[4] Paris XII Univ, H Mondor Hosp, AP HP, Dept Biostat, Creteil, France
[5] Paris XII Univ, H Mondor Hosp, AP HP, Dept Nucl Med, Creteil, France
[6] Paris XII Univ, H Mondor Hosp, AP HP, Dept Radiol, Creteil, France
[7] Paris VII Univ, St Louis Hosp, AP HP, Dept Clin Hematol, Paris, France
[8] Paris VII Univ, St Louis Hosp, AP HP, Dpet Pathol, Paris, France
关键词
diffuse large B-cell lymphoma; germinal center; immunohistochemistry; PET scan; prognosis;
D O I
10.3324/haematol.10895
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives Diffuse large B-cell lymphomas (DLBCL) have a variable outcome, and powerful methods of prognostication are needed in order to choose the best treatment for each patient. Immunophenotypic classification of the tumor as germinal center (GC) or nongerminal center-like (nGC) and early response evaluation with (18)fluorodeoxyglucose positron emission tomography ((18)FDG-PET) scanning have been correlated with survival in DLBCL but the two methods have never been evaluated simultaneously in the same patient population. Our aim was to investigate their respective prognostic values in the same series of patients. Design and Methods We investigated the expression of CD10, Bcl-6, and MUM1 in 81 patients with DLBCL evaluated early with (18)FDG-PET. The tumors were classified as GC or nGC using the algorithm of Hans et al. The results of both methods were correlated with the patients' characteristics and survival. Results CD10 was positive in 27/76 (36%), Bcl-6 in 43/74 (58%), and MUM1 in 33/73 (45%) interpretable cases. Thirty-eight (51%) were in the GC group, and 36 (49%) in the nGC group. With a median follow-up of 33 months, estimated 3-year event-free survival (EFS) of the whole population was 67%. There was no influence of GC/nGC phenotype on survival. Three-year EFS was 46% in the early PET-positive group versus 80% in the PET-negative group (p=0.0003). Interpretation and Conclusions The prognostic value of GC/nGC phenotype is not confirmed in this heterogeneous series, whereas early PET findings are confirmed to be a powerful predictor of outcome. The impact of treatment decisions based on early PET results should be evaluated.
引用
收藏
页码:778 / 783
页数:6
相关论文
共 31 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]   Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma [J].
Barrans, SL ;
Carter, I ;
Owen, RG ;
Davies, FE ;
Patmore, RD ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BLOOD, 2002, 99 (04) :1136-1143
[3]   Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma [J].
Chang, CC ;
McClintock, S ;
Cleveland, RP ;
Trzpuc, T ;
Vesole, DH ;
Logan, B ;
Kajdacsy-Balla, A ;
Perkins, SL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) :464-470
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma [J].
Colomo, L ;
Löpez-Guillermo, A ;
Perales, M ;
Rives, S ;
Martínez, A ;
Bosch, F ;
Colomer, D ;
Falini, B ;
Montserrat, E ;
Campo, E .
BLOOD, 2003, 101 (01) :78-84
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas [J].
De Paepe, P ;
Achten, R ;
Verhoef, G ;
Wlodarska, I ;
Stul, M ;
Vanhentenrijk, V ;
Praet, M ;
De Wolf-Peeters, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7060-7068
[8]  
Fields PA, 2005, HAEMATOLOGICA, V90, P1711
[9]  
Gascoyne RD, 1997, BLOOD, V90, P244
[10]   [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome [J].
Haioun, C ;
Itti, E ;
Rahmouni, A ;
Brice, P ;
Rain, JD ;
Belhadj, K ;
Gaulard, P ;
Garderet, L ;
Lepage, E ;
Reyes, F ;
Meignan, M .
BLOOD, 2005, 106 (04) :1376-1381